Inverness推出能涵盖H5N1的检测方法

 
 
一种A型和B型流感病毒检测列表中包含了禽流感病毒H5N1分离株。该检测方法已经获得了美国食品药品管理局的许可。

这种检测方法是由Binax公司研制开发的，该公司是Inverness医学创新公司(Waltham, MA, USA)的分支机构，该检测方法叫做BinaxNOW流感A和B检测。这种检测是一种一步法快速检测，能够在15分钟之内准确区别出流感病毒A和B型。即配即用型检测能够在流感爆发的时候有效地对患者作出诊断。

经过确证的诊断方法能够帮助医务工作者选择合适的治疗方法，在疾病早期的时候采取干预措施。抗病毒治疗能够减少症状的严重程度，缩短疾病的病程，降低患者传染给其它人的时间。因为开始病毒治疗的时间窗只在出现症状的48小时之内，能够早期诊断的重要性是不言而喻的。

Inverness医疗创新公司是一家在全球范围内处于领先地位的体外诊断产品供应商，该公司现在正在为其水平流体免疫检测和其它用于各种诊断方法的技术开拓机会。

Influenza Panel Includes H5N1
 
A test for influenza A and B now includes avian influenza H5N1 isolates in its list of influenza strains. The test has been cleared by the U.S. Food and Drug Administration (FDA).

The test was developed by Binax Inc., a subsidiary of Inverness Medical Innovations (Waltham, MA, USA), and is called the BinaxNOW influenza A and B test. The test is a one-step, rapid test that is able to clearly differentiate between influenza A and influenza B in 15 minutes. Use of the easy-to-read test can help diagnose patients efficiently in the event of an outbreak of influenza.

A confirmed diagnosis helps healthcare workers to select appropriate treatments and to begin administration early in the process. Antivirals can reduce the severity of symptoms, shorten the duration of illness, and reduce the time during which patients can be infectious to others. Since the window of opportunity to begin antiviral treatment is only 48 hours from the onset of symptoms, these capabilities are very important.

Inverness Medical Innovations is a leading global provider of in vitro diagnostic products that is now exploring new opportunities for its lateral flow immunoassay and other proprietary technologies for various professional diagnostic applications.